Research Analysts Set Expectations for MMSI FY2026 Earnings

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Barrington Research boosted their FY2026 earnings estimates for shares of Merit Medical Systems in a report released on Monday, December 23rd. Barrington Research analyst M. Petusky now expects that the medical instruments supplier will post earnings per share of $4.28 for the year, up from their prior estimate of $4.25. Barrington Research has a “Outperform” rating and a $114.00 price target on the stock. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.36 per share.

Several other brokerages also recently commented on MMSI. Piper Sandler reiterated an “overweight” rating and set a $110.00 price target (up previously from $100.00) on shares of Merit Medical Systems in a report on Monday, September 9th. Wells Fargo & Company upgraded shares of Merit Medical Systems from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $103.00 to $120.00 in a report on Wednesday, December 11th. StockNews.com lowered shares of Merit Medical Systems from a “buy” rating to a “hold” rating in a research report on Sunday, November 3rd. Bank of America lifted their price objective on Merit Medical Systems from $92.00 to $103.00 and gave the stock a “neutral” rating in a research note on Monday, September 16th. Finally, Robert W. Baird increased their target price on Merit Medical Systems from $107.00 to $109.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $105.60.

Merit Medical Systems Stock Up 0.5 %

MMSI stock opened at $98.08 on Wednesday. The company has a current ratio of 5.36, a quick ratio of 3.82 and a debt-to-equity ratio of 0.57. The firm has a market cap of $5.72 billion, a PE ratio of 48.08, a PEG ratio of 2.55 and a beta of 0.84. Merit Medical Systems has a 1 year low of $70.70 and a 1 year high of $108.07. The company has a fifty day simple moving average of $100.84 and a 200 day simple moving average of $94.15.

Merit Medical Systems (NASDAQ:MMSI) last issued its earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.80 by $0.06. Merit Medical Systems had a net margin of 9.05% and a return on equity of 15.61%. The company had revenue of $339.85 million during the quarter, compared to analyst estimates of $334.60 million. During the same quarter last year, the business posted $0.75 EPS. The company’s revenue for the quarter was up 7.8% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Franklin Resources Inc. boosted its position in Merit Medical Systems by 43.0% during the 3rd quarter. Franklin Resources Inc. now owns 559,395 shares of the medical instruments supplier’s stock worth $53,433,000 after buying an additional 168,174 shares during the period. Tidal Investments LLC raised its stake in shares of Merit Medical Systems by 1.0% during the third quarter. Tidal Investments LLC now owns 10,398 shares of the medical instruments supplier’s stock valued at $1,028,000 after acquiring an additional 104 shares during the last quarter. Sanctuary Advisors LLC acquired a new position in shares of Merit Medical Systems during the third quarter worth $207,000. TD Private Client Wealth LLC grew its stake in shares of Merit Medical Systems by 13.9% in the third quarter. TD Private Client Wealth LLC now owns 1,732 shares of the medical instruments supplier’s stock worth $171,000 after purchasing an additional 211 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Merit Medical Systems by 1.3% in the third quarter. Geode Capital Management LLC now owns 1,357,265 shares of the medical instruments supplier’s stock valued at $134,165,000 after purchasing an additional 17,490 shares during the period. Institutional investors and hedge funds own 99.66% of the company’s stock.

Insider Buying and Selling

In related news, CFO Raul Jr. Parra sold 29,646 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $98.02, for a total transaction of $2,905,900.92. Following the sale, the chief financial officer now owns 16,361 shares of the company’s stock, valued at $1,603,705.22. This represents a 64.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director F. Ann Millner sold 12,500 shares of the firm’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.55, for a total value of $1,269,375.00. Following the completion of the transaction, the director now owns 32,391 shares in the company, valued at $3,289,306.05. The trade was a 27.85 % decrease in their position. The disclosure for this sale can be found here. 3.70% of the stock is owned by insiders.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.